PTO/SB/08B (07-05) Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			TENT TO THE REAL PROPERTY.	Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE				Application Number	10/735,256
				Filing Date	December 12, 2003
				First Named Inventor	Stephen M. STRITTMATTER
			PLICANT	Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	Wang, Chang Yu
Sheet	l	of	1	Attorney Docket Number	2159.0420002/EJH/SAC

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No. No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²	
Cyw	AR2	Domeniconi, M., et al., "Myelin-Associated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth," Neuron 35:283-290, Cell Press (July 2002)		
	AS2	GrandPré, T., et al., "Nogo-66 receptor antagonist peptide promotes axonal regeneration," Nature 417:547-551, Nature Publishing Group (May 2002)		
	AT2	International Search Report for International Application No. PCT/US2005/002535, European Patent Office, Netherlands, mailed October 24, 2005		
	AR3	Li, M., et al., "Effect of soluble Nogo reeceptor treatment on functional and histological outcome after spinal cord injury in the rat," Biosis Database, Accession No. PREV200400194121, Abstract No. 80.22, Presented at the 33rd Annual Meeting of the Society of Neuroscience, New Orleans, LA (November 8-12, 2003)		
	AS3	Li, W., et al., "A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin," J. Biol. Chem. 42:43780-43788, The American Society for Biochemistry and Molecular Biology, Inc. (October 2004)		
	АТ3	Li, W., et al., "Neutralization of NGR1 May Be Sufficient to Promote Rat DRG Neurite Outgrowth in the Presence of CNS Myeline," SFN 2003 Abstract Viewer & Itinerary Planner, Program No. 678.3, Presented at the 33rd Annual Meeting of the Society of Neuroscience, New Orleans, LA (November 8-12, 2003)		
GW	AR4	Oertle, T., et al., "Nogo-A Inhibits Neurite Outgrowth and Cell Spreading with Three Discrete Regions," J. Neurosci. 23:5393-5406, Society for Neuroscience (July 2003)		

485763 1.DOC

	Date Considered 2/1/06
--	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.